全文获取类型
收费全文 | 963篇 |
免费 | 52篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 61篇 |
妇产科学 | 19篇 |
基础医学 | 74篇 |
口腔科学 | 16篇 |
临床医学 | 35篇 |
内科学 | 106篇 |
皮肤病学 | 20篇 |
神经病学 | 13篇 |
特种医学 | 140篇 |
外科学 | 433篇 |
综合类 | 25篇 |
预防医学 | 24篇 |
眼科学 | 7篇 |
药学 | 24篇 |
肿瘤学 | 30篇 |
出版年
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2016年 | 6篇 |
2015年 | 15篇 |
2014年 | 11篇 |
2013年 | 11篇 |
2012年 | 17篇 |
2011年 | 26篇 |
2010年 | 34篇 |
2009年 | 35篇 |
2008年 | 26篇 |
2007年 | 46篇 |
2006年 | 60篇 |
2005年 | 41篇 |
2004年 | 60篇 |
2003年 | 34篇 |
2002年 | 42篇 |
2001年 | 50篇 |
2000年 | 23篇 |
1999年 | 27篇 |
1998年 | 23篇 |
1997年 | 39篇 |
1996年 | 22篇 |
1995年 | 27篇 |
1994年 | 22篇 |
1993年 | 10篇 |
1992年 | 34篇 |
1991年 | 42篇 |
1990年 | 34篇 |
1989年 | 38篇 |
1988年 | 27篇 |
1987年 | 26篇 |
1986年 | 11篇 |
1985年 | 12篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1980年 | 12篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1974年 | 1篇 |
排序方式: 共有1029条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Demetrius Ellis Ron Shapiro Mark L. Jordan Velma P. Scantlebury Nisan Gilboa Laszlo Hopp Nancy Weichler Andreas G. Tzakis Richard L. Simmons 《Pediatric nephrology (Berlin, Germany)》1994,8(2):193-200
Clinical aspects of FK-506 or cyclosporine immunosuppression regimens were evaluated in 48 consecutive pediatric renal transplant recipients. Tapering and discontinuation of prednisone was employed only in children receiving FK-506 who experienced minor or no rejection episodes during the 1st posttransplant month. At 1 year follow-up, 17 of 22 (77%) of all children with functioning allografts were receiving no prednisone (n=13) or a mean dosage of 0.07 mg/kg per day (n=4). During the 1st month, acute cellular rejection was more common in the FK-506 group (0.58 vs. 0.21 rejections per patient,P<0.05) but allograft survival (92%) and renal function at 1 year posttransplant were identical in both groups. Compared with the cyclosporine regimen, FK-506 immunosuppression may be associated with a higher incidence of cytomegalovirus or reversible Epstein-Barr virus-induced lymphoproliferative disease. However, the FK-506 group had less hirsutism and gingival hypertrophy and required fewer antihypertensive medications independent of steroid use. Height standard deviation scores and weight-for-height index improved only in preadolescents receiving FK-506 but no prednisone (P<0.02 andP<0.05, respectively), but did not differ between children on FK-506 plus prednisone and those in the cyclosporine group. We conclude that the major advantages of FK-506 over cyclosporine immunosuppression are a reduced severity of hypertension and an improved cosmetic appearance which may improve long-term medical compliance. When used as monotherapy, FK-506 also shows promise in relieving the growth retardation associated with cyclosporine regimens that include prednisone. 相似文献
5.
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. 总被引:29,自引:1,他引:28 下载免费PDF全文
F Greif O L Bronsther D H Van Thiel A Casavilla S Iwatsuki A Tzakis S Todo J J Fung T E Starzl 《Annals of surgery》1994,219(1):40-45
OBJECTIVE: This study analyzed the incidence and timing of biliary tract complications after orthotopic liver transplantation (OLTx) in 1792 consecutive patients. These results were then compared with those of previously reported series. Finally, recommendations were made on appropriate management strategies. SUMMARY BACKGROUND DATA: Technical complications after OLTx have a significant impact on patient and graft survival. One of the principal technical advances has been the standardization of techniques for biliary reconstruction. Nonetheless, biliary complications still occur. A 1983 report from the University of Pittsburgh reported biliary complications in 19% of all transplants, and an update in 1987 reported biliary complications in 13.2% of transplants. METHODS: The medical records of all patients who underwent liver transplantation and were hospitalized between January 1, 1988 and July 31, 1991 were reviewed. The case material consisted of the medical records of 217 patients treated for 245 biliary complications. RESULTS: Primary biliary continuity was established by either choledochocholedochostomy over a T-tube (C-C, n = 129) or a Roux-en-Y choledochojejunostomy with an internal stent (C-RY, n = 85). The overall incidence for biliary complication in this large series was 11.5%. Strictures (n = 93) and bile leak (n = 58) were the most common complications (69.6%). Most biliary complications (n = 143, 66%) occurred within the first 3 months after surgery. In general, leaks occurred early, and strictures developed later. Bile leaks were equally frequent in both C-C and C-RY (27.1% and 25.9%, respectively); strictures were more common after a C-RY type of reconstruction (36.4% and 52.9%, respectively). Twenty-one patients died, an incidence of 9.6%. Fifteen of the 21 biliary-related deaths were among patients treated for rejection before the recognition of biliary tract pathologic findings. CONCLUSIONS: Progress has been made on improving the results of biliary reconstruction after OLTx. Nonetheless, patients continue to experience biliary complications after OLTx, and these complications cause considerable loss of grafts and life. If significant additional improvement in patient and graft survival are to be obtained, the technical performance of OLTx must continue to improve. 相似文献
6.
7.
8.
9.
AG Nettetal 《MedR Medizinrecht》2007,25(11):664-666
Abstrakt 1. Nimmt ein Patient einen ihm von seinem (Zahn-)Arzt einger?umten Exklusiv-Termin nicht wahr, obwohl er auf dessen Eigenschaft
ausdrücklich hingewiesen wurde, so hat er dem (Zahn-)Arzt den Behandlungsausfall abzüglich eines angemessenen Eigenanteils
des (Zahn-)Arztes zu ersetzen.
2. Die Ersatzpflicht tritt auch dann ein, wenn der Patient den Termin nicht in der in dem Behandlungsvertrag vorgesehenen
Frist absagt. Eine hierfür seitens des (Zahn-)Arztes bestimmte Frist von zwei Tagen vor Behandlungsbeginn stellt sich für
den Patienten grunds?tzlich auch nicht als unangemessene Benachteiligung i.S. des § 307 BGB dar.
3. Ein Anspruch des Arztes entf?llt auch bei nur mündlicher Vereinbarung nicht unter dem Gesichtspunkt des § 4 Abs. 5b BMV-Z,
denn diese Vorschrift ist teleologisch dahin zu reduzieren, dass nur zahn?rztliche Honoraransprüche aus erfolgten Behandlungen
schriftlich vereinbart werden müssen. Soweit es jedoch um einen vertraglichen Anspruch wegen einer Leistungsst?rung geht,
vermag das Schriftformerfordernis des § 4 Abs. 5b BMV-Z grunds?tzlich nicht einzugreifen. (Leits?tze des Bearbeiters) 相似文献
10.
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. 总被引:1,自引:0,他引:1 下载免费PDF全文
S Todo J J Fung T E Starzl A Tzakis H Doyle K Abu-Elmagd A Jain R Selby O Bronsther W Marsh et al. 《Annals of surgery》1994,220(3):297-309
OBJECTIVE: The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined. SUMMARY BACKGROUND DATA: After 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejection with conventional immunosuppression, then as a primary drug. METHODS: Between August 1989 and December 1993, 1391 recipients (1188 adult and 203 pediatric) of primary liver allografts were treated with FK 506 from the outset. Results from these patients were analyzed and compared with those of 1212 historical control patients (971 adult and 241 pediatric) given cyclosporine-based immunosuppression. RESULTS: Actuarial survival at 4 years was 86.2% with FK 506 versus 65.5% with cyclosporine in the pediatric patients (p < 0.0000) and 71.4% versus 65.5% in the adults (p < 0.0005). The need for retransplantation was reduced significantly for FK 506 patients. Four-year graft survival was 77.0% with FK 506 versus 48.4% with cyclosporine in the pediatric patients (p < 0.0000), and 61.9% with FK 506 versus 51.4% with cyclosporine in the adult recipients (p < 0.0000). Regression analysis revealed that reduction in mortality or graft loss from uncontrollable rejection, sepsis, technical failure, and recurrent original liver disease were responsible for the improved results with FK 506 therapy. CONCLUSIONS: FK 506 is a potent and superior immunosuppressive agent for orthotopic liver transplantation. 相似文献